School of Medicine


Showing 21-40 of 44 Results

  • Abby C. King

    Abby C. King

    David and Susan Heckerman Professor and Professor of Epidemiology & Population Health and of Medicine (Stanford Prevention Research Center)

    Current Research and Scholarly InterestsMy interests include applications of behavioral theory and social ecological approaches to achieve large scale changes impacting chronic disease prevention and control; expanding the reach and translation of evidence-based interventions through state-of-the-art technologies; exploring social and physical environmental influences on health; applying community participatory research perspectives to address health disparities; and policy-level approaches to health promotion/disease prevention.

  • Allison W. Kurian, M.D., M.Sc.

    Allison W. Kurian, M.D., M.Sc.

    Professor of Medicine (Oncology) and of Epidemiology and Population Health

    Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.

  • Uri Ladabaum

    Uri Ladabaum

    Professor of Medicine (Gastroenterology and Hepatology)

    Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.

  • Marvin Langston

    Marvin Langston

    Assistant Professor of Epidemiology and Population Health

    BioDr. Langston joined the faculty in the Department of Epidemiology and Population Health in 2022. He received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine. Dr. Langston focuses on the epidemiology of benign and malignant prostate conditions. His long-term goal is to harmonize molecular and clinical aspects of urological condition diagnoses to produce well-characterized outcomes for biomarker discovery and etiological investigation.

  • Jennifer Lee

    Jennifer Lee

    Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsI am a clinical scientist (PhD epidemiology), endocrinologist, and CMO at VAPA Cooperative Studies Program Coordinating Center. My group does pattern and prediction mapping along the life-course of interventions/outcomes and how healthcare system can positively impact health longitudinally. We use novel molecular epi, 'big' data like EHRs using multiple designs/methods/technologies. These interests cut across multiple complex chronic diseases and lifespan.
    https://med.stanford.edu/jleelab.html

  • Eleni Linos, MD, MPH, DrPH

    Eleni Linos, MD, MPH, DrPH

    Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health

    BioEleni Linos MD, MPH, DrPH, is the Director of the Center for Digital Health and Professor of Dermatology and Epidemiology at Stanford University.

    Dr. Linos' work focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. Dr. Linos is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients. She received her medical degree from Cambridge and Oxford universities in the UK, then trained in epidemiology at the Harvard School of Public Health and completed her residency at Stanford.

  • Karl Lorenz

    Karl Lorenz

    Professor of Medicine (Primary Care and Population Health)

    BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.

  • Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

    Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsWe conduct clinical trials and epidemiological, translational, and real-world studies of liver cancer, fatty liver (NASH, NAFLD), viral hepatitis B and C, liver cirrhosis, and liver transplant. We focus on risk identification for disease prevention and treatment for improvement of survival. We focus on sex, racial/ethnic, and socioeconomic disparities. We specialize in clinical trials, large international real-world consortium registry data, and large public/semi-public databases.

  • Doug Owens

    Doug Owens

    Henry J. Kaiser, Jr. Professor, Senior Fellow at the Freeman Spogli Institute for International Studies and Professor, by courtesy, of Management Science and Engineering

    Current Research and Scholarly InterestsMy research uses decision modeling, cost-effectiveness analysis, and meta-analysis to evaluate clinical and health policy problems. Much of my work involves development of national guidelines for prevention and treatment.

  • VJ Periyakoil, Professor of Medicine

    VJ Periyakoil, Professor of Medicine

    Professor of Medicine (Primary Care and Population Health)

    Current Research and Scholarly InterestsMy research focuses on the intersection of biological, psychosocial and cultural aspects of care of persons with chronic and serious illnesses including dementia.

  • Judith Prochaska

    Judith Prochaska

    Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)

    Current Research and Scholarly InterestsDr. Prochaska's research expertise centers on technology-mediated health behavior change interventions including targets of tobacco, physical activity, and dietary change. Working with Alaska Native and Latino communities, people with serious mental illness, alcohol and drug problems, or heart disease, and jobseekers and the unhoused, Dr. Prochaska’s research combines stage-tailored interventions with pharmacotherapy and utilizes interactive expert system interventions and social media.

  • David Rehkopf

    David Rehkopf

    Associate Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Sociology, of Pediatrics and of Health Policy

    BioI am a social epidemiologist and serve as an Associate Professor in the Department of Epidemiology and Population Health and in the Department of Medicine in the Division of Primary Care and Population Health. I joined the faculty at Stanford School of Medicine in 2011.

    I am Director of the Stanford Center for Population Health Sciences. In this position, I am committed to making high-value data resources available to researchers across disciplines in order to better enable them to answer their most pressing clinical and population health questions.

    My own research is focused on understanding the health implications of the myriad decisions that are made by corporations and governments every day - decisions that profoundly shape the social and economic worlds in which we live and work. While these changes are often invisible to us on a daily basis, these seemingly minor actions and decisions form structural nudges that can create better or worse health at a population level. My work demonstrates the health implications of corporate and governmental decisions that can give the public and policy makers evidence to support new strategies for promoting health and well-being. In all of his work, I have a focus on the implications of these exposures for health inequalities.

    Since often policy and programmatic changes can take decades to influence health, my work also includes more basic research in understanding biological signals that may act as early warning signs of systemic disease, in particular accelerated aging. I examine how social and economic policy changes influence a range of early markers of disease and aging, with a particular recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop new more sensitive ways to understand the health implications of social and economic policy changes.

  • Thomas Robinson

    Thomas Robinson

    The Irving Schulman, M.D. Professor of Child Health, Professor of Medicine (Stanford Prevention Research Center) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsDr. Robinson originated the solution-oriented research paradigm and directs the Stanford Solutions Science Lab. He is known for his pioneering obesity prevention and treatment research, including the concept of stealth interventions. His research applies social cognitive models of behavior change to behavioral, social, environmental and policy interventions for children and families in real world settings, making the results relevant for informing clinical and public health practice and policy.

  • Lisa Goldman Rosas

    Lisa Goldman Rosas

    Assistant Professor (Research) of Epidemiology and Population Health and of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics

    BioLisa Goldman Rosas, PhD MPH is an Assistant Professor in the Department of Epidemiology and Population Health and the Department of Medicine, Division of Primary Care and Population Health at Stanford School of Medicine. An epidemiologist by training, Dr. Goldman Rosas’ research focuses on addressing disparities in chronic diseases such as diabetes, heart disease, depression, and cancer among racial/ethnic minority families. This research features rigorous quantitative and qualitative methodologies, participatory qualitative approaches, and shared leadership with patient and community partners. She is passionate about integrating patients, caregivers, community organizations, and other key stakeholders in the research process in order to affect the greatest improvements in health and well-being. As a reflection of this passion, Dr. Goldman Rosas serves as the Faculty Director for the School of Medicine Office of Community Engagement, Co-Director of Community-Engaged Research for the Office of Cancer Health Equity, and Director of the Outreach, Recruitment and Engagement Core for the Alzheimer's Disease Research Center. In these roles, she supports other faculty and patient and community partners to develop sustainable and meaningful partnerships to support transformative research. In addition to research, she teaches at the undergraduate and graduate levels and has a special focus on increasing diversity in biomedical research.

  • Lidia Schapira

    Lidia Schapira

    Professor of Medicine (Oncology)

    BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.

  • Nigam H. Shah, MBBS, PhD

    Nigam H. Shah, MBBS, PhD

    Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science

    Current Research and Scholarly InterestsWe analyze multiple types of health data (EHR, Claims, Wearables, Weblogs, and Patient blogs), to answer clinical questions, generate insights, and build predictive models for the learning health system.

  • Michael Snyder, Ph.D.

    Michael Snyder, Ph.D.

    Stanford W. Ascherman Professor of Genetics

    Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states

  • Samuel So, MD

    Samuel So, MD

    Lui Hac Minh Professor in the School of Medicine

    Current Research and Scholarly InterestsThrough a 4 pronged comprehensive program: translational and clinical research, early detection and treatment, promoting education, awareness and immunization and building partnership, we are working towards the development of new strategies that will lead to the elimination of hepatitis B worldwide and reduce the threat and incidence of liver cancer. Current research efforts focus on evaluating potential new diagnostic and treatment markers and novel targeted therapy for primary liver cancer.

  • David Spiegel

    David Spiegel

    Jack, Lulu and Sam Willson Professor of Medicine

    Current Research and Scholarly InterestsDr. Spiegel's research program involves mind/body interactions, including cancer progression, the response to traumatic stress, and the effect of hypnosis on the perception of pain and anxiety.